Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Hutchison China MediTech said it had begun a clinical trial for its drug that deals with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.
The first ITP patient was dosed on August 12, 2019 in China.
The study, a randomized, double-blinded, placebo-controlled Phase Ib clinical trial was investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of the company's drug HMPL-523 used to treat adults with immune thrombocytopenia.
The primary endpoint of the study was based on the number of patients with any adverse event. The secondary endpoints were maximum plasma concentration area under the concentration-time curve in a selected time interval and rate of clinical remission at week 8, the company said.
Approximately 50 to 60 patients would be enrolled, the company added.
At 8:40am: (LON:HCM) Hutchison China Meditech Ltd share price was -0.75p at 333.75p